[Li Qiang Signs State Council Decree Promulgating Revised "Regulations for the Implementation of the Drug Administration Law of the People's Republic of China"] Premier Li Qiang recently signed a State Council decree promulgating the revised "Regulations for the Implementation of the Drug Administration Law of the People's Republic of China," which will come into effect on May 15, 2026. The Regulations consist of 9 chapters and 89 articles. The main revisions are as follows: First, improving the drug research and registration system. Supporting clinically value-oriented drug research and innovation, encouraging research and creation of new drugs, and supporting the clinical promotion and use of new drugs. Second, strengthening drug production management. Strictly managing contract manufacturing of drugs and reinforcing the responsibilities of drug marketing authorization holders in contract manufacturing. Third, standardizing drug distribution and use. Improving the management system for online drug sales and reinforcing the responsibilities of third-party platform providers for online drug transactions. Fourth, strictly regulating drug safety supervision. Clarifying drug safety supervision and inspection measures.
